MMX mesalamine: A novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 6, 2008, Pages 1049-1058

  Hu, Mary Y ^a   Peppercorn, Mark A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

5 aminosalicylate; Compliance; High dose; Lialda ; Mesalamine; MMX; Multi matrix; Once daily; Remission induction; Sustained release; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MERCAPTOPURINE; MESALAZINE; MEZAVANT; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; POLYMETHACRYLIC ACID; PROSTAGLANDIN SYNTHASE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; BONE MARROW TOXICITY; CANCER RISK; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIARRHEA; DISEASE EXACERBATION; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FLATULENCE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERSENSITIVITY; INTERSTITIAL NEPHRITIS; LEUKOPENIA; NAUSEA; NEPHROTOXICITY; PANCREATITIS; PATIENT COMPLIANCE; PERICARDITIS; PNEUMONIA; RASH; REVIEW; RISK REDUCTION; TABLET FORMULATION; THROMBOCYTOPENIA; ULCERATIVE COLITIS; VERNER MORRISON SYNDROME;

CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; GASTROINTESTINAL AGENTS; HUMANS; MESALAMINE; PATIENT COMPLIANCE;

EID: 42649140899     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.6.1049     Document Type: Review

References (64)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48(4):526-35
2. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99(7):1371-85
3. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940 - 1993: incidence, prevalence, and survival. Gut 2000;46(3):336-43
4. Ghosh S, Shand A, Ferguson A. Ulcerative colitis. BMJ 2000;320(7242):1119-23
5. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23(5):577-85
6. Lim WC, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord 2004;4(3):104-17
7. Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 2007;4(3):160-70
8. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972;181(3):555-62
9. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;2:CD000544
10. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;2:CD000543
11. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995;9(3):293-300
12. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95(5):1263-76
13. Safdi M, Demicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92(10):1867-71
14. D'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997;92(7):1143-7
15. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54(7):960-5
16. Piodi LP, Ulivieri FM, Cermesoni L, Cesana BM. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 2004;39(2):154-7
17. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100(6):1345-53
18. Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf 2007;6(2):99-107
19. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19(2):179-89
20. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96(10):2929-33
21. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(2):191-8
22. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8(12):1179-83
23. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114(1):39-43
24. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007;102(7):1417-26
25. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98(7):1535-44
26. Once-daily mesalamine (Lialda) for ulcerative colitis. Med Lett Drugs Ther 2007;49(1257):25-6
27. Baker DE. MMX mesalamine. Rev Gastroenterol Disord 2006;6(3):146-52
28. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005;11(5):421-7
29. Brunner M, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003;17(3):395-402
30. Tenjarla S, Romasanta V, Zeijdner E, et al. Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv Ther 2007;24(4):826-40
31. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 2000;95(12):3343-5
32. Nikolaus S, Folscn U, Schreiber S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000;47(31):71-82
33. Bantel H, Berg C, Vieth M, et al. Mesalazine inhibits activation of transcription factor NF-kappa B in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95(12):3452-7
34. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic add is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005;201(8):1205-15
35. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):10-4
36. Shire Pharmaceuticals, Inc. Lialda™ prescribing information. Wayne, PA: Shire Pharmaceuticals; 2007
37. Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001;15(1):55-62
38. Corey AE, Rose GM, Conklin JD. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine. J Int Med Res 1990;18(6):441-53
39. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17(1):29-42
40. Bondesen S. Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease. Pharmacol Toxicol 1997;81(Suppl 2):1-28
41. Zhou SY, Fleisher D, Pao LH, et al. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999;27(4):479-85
42. Lichtenstein GR, Sandborn WJ, Kamm MA, et al. MMX mesalamine, a novel formulation of 5-ASA, effectively induces the remission of active mild-to-moderate ulcerative colitis in men and women [abstract 1103]. American College of Gastroenterology Annual Scientific Meeting; Las Vegas, NV; October 2006
43. D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006;24(7):1087-97
44. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132(1):66-75;quiz 432-33
45. Lichtenstein GR, Kamm MA, Boddu P et al.: Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5(1):95-102
46. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX multi-matrix system mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007;26(2):205-15
47. Sandborn WJ, Karlstadt R, Barrett K, et al. Time to initial symptom resolution with MMX mesalamine therapy for active, mild-to-moderate ulcerative colitis [abstract 619]. American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA; October 2007
48. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. Once- and twice-daily SPD476, a novel, high-strength formulation of 5-ASA, induces remission of both mild and moderate ulcerative colitis: a prespecified analysis of combined data from two pivotal, randomized, placebo-controlled, phase III studies [abstract T1147]. Digestive Disease Week; Los Angeles, CA; May 2006
49. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. SPD476, a novel formulation of 5-ASA given once or twice daily, is effective for the induction of remission of left-sided and extensive ulcerative colitis: an analysis of combined data from two pivotal, randomized, placebo-controlled phase III studies [abstract T1148]. Digestive Disease Week; Los Angeles, CA; May 2006
50. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993;88(8):1188-97
51. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine ar 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100(11):2478-85
52. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med 1991;115(5):350-5
53. Kamm MA, Colombel J, Kornbluth A, et al. A randomized comparison of once- versus twice-daily MMX mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis [abstract T1296]. Digestive Disease Week; Washington, DC; May 2007
54. Kamm MA, Hanauer SB, Lichtenstein GR, et al. MMX mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis: outcome in patients treated over 14 - 16 months [abstract T1297]. Digestive Disease Week; Washington, DC; May 2007
55. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med 1996;124(2):204-11
56. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995;40(2):296-304
57. Panaccione R, Kamm MA, Karlstadt R, et al. Once- or twice-daily MMX mesalamine for the maintenance of remission of mild or moderate ulcerative colitis [abstract 950]. American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA; October 2007
58. Lichtenstein GR, Kamm MA, Karlstadt R, et al. MMX mesalamine is effective for the maintenance of ulcerative colitis remission in both left-sided and extensive disease [abstract 949]. American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA; October 2007
59. Lichtenstein GR, Diebold R, Karlstadt R, et al. The effect of sigmoidoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to-moderate ulcerative colitis [abstract T1284]. Digestive Disease Week; Washington, DC; May 2007
60. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. MMX mesalamine is well tolerated in patients with active mild-to-moderate ulcerative colitis: pooled analysis of adverse events from three randomized studies [abstract 1104]. American College of Gastroenterology Annual Scientific Meeting; Las Vegas, NV; October 2006
61. Lichtenstein GR, Butler T, Barrett K, et al. MMX mesalamine for maintaining remission of ulcerative colitis: interim safety results [abstract 1106]. American College of Gastroenterology Annual Scientific Meeting; Las Vegas, NV; October 2006
62. Proctor & Gamble Pharmaceuticals, Inc. Asacol® prescribing information. Cincinnati, OH: Proctor & Gamble; 2006
63. Shire Pharmaceuticals, Inc. Pentasa® prescribing information. Wayne, PA: Shire Pharmaceuticals; 2007
64. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003;1(3):170-3